Roth Capital Comments on ICU Medical Inc.’s Q4 2017 Earnings (ICUI)
ICU Medical Inc. (NASDAQ:ICUI) – Stock analysts at Roth Capital cut their Q4 2017 earnings per share estimates for shares of ICU Medical in a research report issued to clients and investors on Thursday. Roth Capital analyst C. Lewis now expects that the brokerage will post earnings of $1.05 per share for the quarter, down from their previous estimate of $1.10.
A number of other equities analysts have also weighed in on the company. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $119.00 price target (up previously from $115.00) on shares of ICU Medical in a research report on Thursday, August 11th. Zacks Investment Research lowered ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th.
Shares of ICU Medical (NASDAQ:ICUI) traded up 2.97% during trading on Friday, hitting $148.98. 358,960 shares of the stock were exchanged. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 44.37 and a beta of 0.37. The firm has a 50 day moving average of $125.42 and a 200-day moving average of $112.09. ICU Medical has a 12-month low of $85.56 and a 12-month high of $149.21.
ICU Medical (NASDAQ:ICUI) last announced its earnings results on Monday, August 8th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $89.66 million. ICU Medical had a net margin of 14.94% and a return on equity of 10.33%. The company’s quarterly revenue was up 15.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 EPS.
In other ICU Medical news, VP Thomas D. Mccall sold 2,071 shares of the firm’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $126.07, for a total transaction of $261,090.97. Following the completion of the sale, the vice president now directly owns 2,129 shares in the company, valued at approximately $268,403.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott E. Lamb sold 1,474 shares of the firm’s stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $121.61, for a total value of $179,253.14. Following the sale, the chief financial officer now owns 4,705 shares of the company’s stock, valued at $572,175.05. The disclosure for this sale can be found here. Company insiders own 15.90% of the company’s stock.
A number of large investors have recently made changes to their positions in the company. Eqis Capital Management Inc. raised its stake in shares of ICU Medical by 86.3% in the third quarter. Eqis Capital Management Inc. now owns 4,675 shares of the company’s stock worth $591,000 after buying an additional 2,166 shares during the last quarter. Mason Street Advisors LLC acquired a new stake in shares of ICU Medical during the second quarter worth approximately $319,000. Royal Bank of Canada raised its stake in shares of ICU Medical by 57.2% in the second quarter. Royal Bank of Canada now owns 207,226 shares of the company’s stock worth $23,365,000 after buying an additional 75,396 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of ICU Medical by 4.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 48,889 shares of the company’s stock worth $5,513,000 after buying an additional 2,004 shares during the last quarter. Finally, Stifel Financial Corp raised its stake in shares of ICU Medical by 10.9% in the second quarter. Stifel Financial Corp now owns 67,649 shares of the company’s stock worth $7,627,000 after buying an additional 6,656 shares during the last quarter. Hedge funds and other institutional investors own 89.50% of the company’s stock.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Stock Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related stocks with our FREE daily email newsletter.